Shots:
Inventiva will receive $12M up front and is eligible to receive ~$5M in clinical milestones, and ~$290M in clinical, regulatory, and commercial milestones along with royalties. The companies collaborated on lanifibranor to treat NASH and other metabolic diseases in mainland China, Hong Kong, Macau, and Taiwan (Greater China)
Sino Biopharm gets an exclusive right to develop, manufacture, and commercialize lanifibranor in Greater China for NASH & other metabolic diseases. CTTQ (a subsidiary of Sino Biopharm) will bear all costs associated with the trials conducted in Greater China
Inventiva’s lanifibranor is being studied in the P-III (NATiV3) trial for the same indication. The therapy has received BTD & FTD for NASH
